- In October 2024, Booster Therapeutics, a Berlin-based biotech startup, emerged from stealth with USD 15 million in seed financing, led by Apollo Health Ventures and Novo Holdings. The company is focusing on developing a novel class of small molecule therapies that activate the 20S proteasome, a key cellular component responsible for degrading damaged and misfolded proteins This innovative approach aims to target neurodegenerative diseases such as Parkinson’s and Alzheimer’s, where protein accumulation plays a pivotal role in disease progression
- In April 2024, Bristol Myers Squibb and 2seventy bio, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. The approval was based on results from the KarMMa-3 trial and is expected to enhance treatment options for patients with complex disease histories
- In March 2023, Kezar Life Sciences secured patent protection for various salts and polymorphs of Zetomipzomib in multiple countries, including Australia, Chile, Eurasia, Japan, Mexico, and Taiwan, marking a significant milestone in the company’s efforts to expand its intellectual property portfolio for proteasome inhibitor therapies
- In October 2022, Karyopharm Therapeutics Inc., a U.S.-based pharmaceutical company, entered into a collaboration with Bristol-Myers Squibb to evaluate mezigdomide in patients who have received prior treatments. This partnership represents a strategic effort to drive forward research and development within the proteasome inhibitors market, leveraging the expertise of both companies to improve therapeutic outcomes
